IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS
Launched by JIE QIAO · Mar 6, 2018
Trial Information
Current as of May 10, 2025
Unknown status
Keywords
ClinConnect Summary
A single center, randomized controlled clinical trial will enroll 350 couples with PCOS undergoing their first cycle of IVF. The participation in this study will be approximately 2 years with a total of 7 visits from the cycle beginning, pregnancy to delivery. On day 2 or day 3 following the onset of menstrual bleeding, eligible patients will be allocated to two groups at a ratio of 1:1- IVM protocol, and standard IVF protocol. All participants will be randomized through stratified block randomization according to the study sites.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Infertile couples scheduled for their first IVF cycle.
- • 2. Women diagonosed with polycystic ovarian syndrome.
- • 3. Voluntary participation and informed consent obtained.
- Exclusion Criteria:
- • 1. Couple with contraindication for IVF or ICSI.
- • 2. Couples receiving donor sperm or donor eggs.
- • 3. Couples with indications or have plan to receive PGD and PGS.
- • 4. Sperm analysis diagnosed as azoospermia;
- • 5. Either male partner or female partner with an abnormal chromosome karyotype (chromosome polymorphisms was not included).
- • 6. Women who have undergone unilateral ovariectomy.
About Jie Qiao
Jie Qiao is a leading clinical trial sponsor dedicated to advancing medical research and innovation through the development and execution of high-quality clinical studies. With a focus on patient-centered approaches and rigorous scientific methodologies, Jie Qiao collaborates with healthcare professionals and regulatory authorities to ensure the safety and efficacy of new therapies. Their commitment to ethical standards and transparency drives their mission to deliver meaningful advancements in healthcare, ultimately improving patient outcomes and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Jie Qiao
Study Director
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials